HALOZYME THERAPEUTICS, INC. Current Portion of Long-Term Debt
HALOZYME THERAPEUTICS, INC. (HALO) had Current Portion of Long-Term Debt of $208.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LongTermDebtCurrent · last filed 2026-08-06
- 2026-06-30: Long-term Debt, Current Maturities $208.97M.
- 2026-03-31: Long-term Debt, Current Maturities $208.74M.
- 2025-12-31: Long-term Debt, Current Maturities $0.00.
- 2025-09-30: Long-term Debt, Current Maturities $710.68M.
| Period end | Long-term Debt, Current Maturities |
|---|---|
| 2026-06-30 | $208.97M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $208.74M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | $710.68M 10-Q · filed 2025-11-03 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-03 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-20 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 |
| 2022-12-31 | $13.33M 10-K · filed 2024-02-20 |
| 2022-09-30 | $13.31M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $99.05M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $89.55M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $89.42M 10-K · filed 2023-02-21 |
| 2021-09-30 | $89.25M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $89.17M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $89.04M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $397.23M 10-K · filed 2022-02-22 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-02 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.86M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $19.54M 10-K · filed 2021-02-23 |
| 2019-09-30 | $54.54M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $70.88M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $86.66M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $91.51M 10-K · filed 2020-02-24 |
| 2018-09-30 | $88.52M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $86.97M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $82.46M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $77.21M 10-K · filed 2019-02-21 |
| 2017-09-30 | $61.43M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $45.52M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $29.60M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $17.39M 10-K · filed 2018-02-20 |
| 2016-09-30 | $12.39M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $3.29M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $27.42M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $21.86M 10-K · filed 2017-02-28 |
| 2015-09-30 | $15.70M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $9.66M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $3.73M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2014-09-30 | $10.07M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $6.20M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $2.40M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $0.00 10-Q · filed 2014-11-10 |
| 2013-09-30 | $5.97M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $3.64M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $1.36M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $0.00 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |